Weight Regain After Stopping GLP-1 Medications: How Much and How Fast?

A large retrospective study found that patients who stopped GLP-1 medications regained weight, but the rate and extent depended on how long they had been on the drugs.

Alexander, G Caleb et al.·Obesity (Silver Spring·2026·
RPEP-147382026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Patients experienced weight regain after discontinuing GLP-1 medications, with patterns influenced by the duration of prior treatment.

Key Numbers

How They Did This

Retrospective cohort study using TriNetX electronic health records (2014-2023) with linear mixed effects models and propensity score adjustment.

Why This Research Matters

Understanding weight regain patterns after stopping GLP-1 drugs is critical for setting patient expectations and planning long-term treatment strategies.

The Bigger Picture

Weight regain after stopping GLP-1 medications is a central concern in obesity medicine. This data supports the emerging view that obesity may require ongoing pharmacotherapy, similar to other chronic conditions.

What This Study Doesn't Tell Us

Retrospective design using EHR data; reasons for discontinuation unknown; BMI measurements may be irregular in real-world records.

Questions This Raises

  • ?Is there a minimum treatment duration that protects against rapid weight regain?
  • ?Can lifestyle interventions during GLP-1 use reduce the magnitude of post-discontinuation regain?

Trust & Context

Key Stat:
Weight regain after discontinuation Pattern and extent influenced by duration of prior GLP-1 use
Evidence Grade:
Retrospective cohort study — provides real-world evidence but cannot establish causation. Subject to confounding despite statistical adjustments.
Study Age:
Published 2026 in Obesity. Uses data through November 2023.
Original Title:
Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.
Published In:
Obesity (Silver Spring, Md.), 34(2), 482-490 (2026)
Database ID:
RPEP-14738

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do you gain all the weight back after stopping GLP-1 drugs?

This study found weight regain does occur after stopping GLP-1 medications, but the amount and speed depend on how long the patient was on the medication.

Does this mean you have to take GLP-1 drugs forever?

The findings support treating obesity as a chronic condition that may require ongoing pharmacotherapy, though individual strategies should be discussed with a healthcare provider.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-14738·https://rethinkpeptides.com/research/RPEP-14738

APA

Alexander, G Caleb; Xu, Yizhen; Xiao, Xuya; Lewis, Sydney V; Zeger, Scott; Mehta, Hemalkumar B. (2026). Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.. Obesity (Silver Spring, Md.), 34(2), 482-490. https://doi.org/10.1002/oby.70076

MLA

Alexander, G Caleb, et al. "Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.." Obesity (Silver Spring, 2026. https://doi.org/10.1002/oby.70076

RethinkPeptides

RethinkPeptides Research Database. "Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist..." RPEP-14738. Retrieved from https://rethinkpeptides.com/research/alexander-2026-weight-changes-from-glucagonlike

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.